Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18465773 | 0.87 | MAPT (0.50) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL10832273 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL7695939 | 0.85 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL23491961 | 0.84 | MTNR1A (0.54) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL22511314 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL16650924 | 0.84 | PPID (0.56) | ALDH1A1MAPK1L3MBTL1KMT2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL8053510 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL7285559 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL19244038 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL2135402 | 0.82 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597400-B2 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof | ABBVIE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190322677-A1 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | ABBVIE INC. | 2019-10-24 | — | — | US | disclosed |
| EP-3063162-B1 | GLUCOPYRANOSYL-SUBSTITUTED INDOLE-UREA DERIVATIVES AND THEIR USE AS SGLT INHIBITORS | LILLY CO ELI (US) | 2017-08-16 | — | — | EP | disclosed |
| US-6124329-A | AN ENZYME INHIBITOR FOR THE TREATMENT OR PROPHYLAXIS OF TISSUE BREAKDOWN, FOR EXAMPLE RHEUMATOID ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR, MULTIPLE SCLEROSIS | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2000-09-26 | — | — | US | disclosed |
| US-5962529-A | OSTEOPOROSIS; RHEUMATIC DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; SKIN DISORDERS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| EP-0766664-A2 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-04-09 | — | — | EP | disclosed |
| WO-1995035275-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597400-B2 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof | CNKSR1, JAK3, JAK2 | ALDH1A1 1068/4885MAPK1 3081/4885L3MBTL1 4748/4885 |
| US-20190322677-A1 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | CNKSR1, JAK2, TNF | ALDH1A1 600/4885MAPK1 3184/4885L3MBTL1 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.